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Objective: C-reactive protein (CRP) is considered a useful serum marker for patients with RCC. However, its clinical
utility in advanced metastatic renal cell carcinoma (AM-RCC), particularly in deciding whether to perform
nephrectomy at the onset, is not well studied.
Patients and methods: We retrospectively evaluated 181 patients with AM-RCC, including 18 patients underwent
potentially curative surgery, 111 underwent cytoreductive nephrectomy, and 52 received medical treatment only.
CRP cutoff points were determined by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier and
Cox regression analyses were used for survival tests.
Results: ROC analysis suggested that grouping patients according to 3 CRP ranges was a rational model. Patients
with highly elevated CRP (≥67.0 mg/L) presented remarkably poor prognosis despite treatment (nephrectomy or
medical treatment only). Cox regression models demonstrated that risk factors of overall survival for patients who
underwent nephrectomy were the CRP ranges defined in this study (≤18.0 mg/L, >18.0 and <67.0 mg/L, and
≥67.0 mg/L), ECOG PS (0, 1, and ≥2), and number of metastatic organ sites (0–1 and ≥2). The retrospective design
is a limitation of this study.
Conclusion: Our study demonstrated that the serum CRP level is a statistically significant prognostic parameter
for patients with AM-RCC. The data also indicated that pretreatment serum CRP level provides useful prognostic
information that helps in deciding whether to perform initial nephrectomy for patients with AM-RCC.
Keywords: C-reactive protein, Rena cell carcinoma, PrognosisBackground
Advanced metastatic-renal cell carcinoma (AM-RCC) is
associated with a poor prognosis, with the 5-year sur-
vival rate being less than 20% for patients presenting
with stage IV disease [1,2]. RCC is known to be resistant
to conventional chemotherapy and radiation. Cytokine-* Correspondence: pug_daikichi@yahoo.co.jp
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reproduction in any medium, provided the orbased immunotherapies, including interferon-alpha (IFN-α)
and interleukin-2 (IL-2), elicited limited response in a
small subset of AM-RCC cases [3,4]. Over the last few
years, novel molecular targeting agents, such as antiangio-
genic drugs and mammalian target of rapamycin (mTOR)
inhibitors, have been developed, and they have assumed a
predominant role in the several treatment options cur-
rently available for AM-RCC. On the other hand, surgical
interventions, including cytoreductive nephrectomy and/
or metastasectomy, have also proven to be beneficial toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathologic characteristics of patients with
advanced metastatic RCC treated with any kind of






Number of patients (%) 129 (71.3) 52 (28.7)
Age, yr
Median 62 67.5 0.006*
Range 30–81 36–86
Sex
Female 33 15 0.780**
Male 96 37
PS
0 64 14 <0.001*
1 57 20
≥2 8 18
No. of metastatic organ sites





Lung 68 30 0.657**
Bone 46 13 0.227**
Lymph node 31 19 0.089**
Liver 4 7 0.008**
CNS 4 4 0.174**
Others 17 7 0.856*
Median 8.00 9.25 0.008*
Range 2.50– 24.0
Histopathology




Sarcomatoid change 3 5
Others or not determined 8 30






*Mann-Whitney U test; **Chi-square test.
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survival and quality of life [3-5]. Surgical removal of the
majority of tumor burden can be expected to diminish
the source of tumor-promoting growth factors or
immunosuppressive cytokines, although this has not yet
been confirmed [3,4]. Currently, an important concern is
that no consensus has been established on the criteria for
identifying patients with AM-RCC who are most likely
to benefit from nephrectomy and/or metastasectomy
performed at the onset [4-7].
C-reactive protein (CRP) is an acute-phase reactant
protein exclusively synthesized by hepatocytes. The
serum concentration of CRP rises as much as 1000-fold
in immediate response to cytokines or chemical media-
tors released in various pathological conditions, includ-
ing acute inflammation, infection, tissue or cell necrosis,
and some malignancies [7,8]. Several studies have reported
that CRP is a useful serum marker for patients with RCC,
and elevated serum CRP levels have been shown to be
associated with tumor aggressiveness, recurrence, and
poor prognosis [8-11]. However, its clinical utility in AM-
RCC, particularly in deciding whether to perform surgical
interventions at the onset, has not been studied well. We
retrospectively investigated the role of CRP as a prog-
nostic marker for patients with AM-RCC. We also
explored its usefulness in identifying patients who are
most likely to benefit from early nephrectomy.
Methods
Patients and treatment
Eligibility for the study was defined as the presence of
clinical or pathologic T4, nodal or organ metastatic RCC
when the condition was first diagnosed. A total of 181
patients who were treated at our hospitals for AM-RCC
between April 1989 and June 2009 were enrolled in the
study. The study was conducted in accordance with the
principles espoused by the Declaration of Helsinki and all
local regulations. The study protocol (#B110901012) was
approved by the institutional ethics committee of the
Yokohama City University Hospital. Among 181 AM-
RCC patients, 18 patients (9.90%) underwent potentially
curative surgeries, i.e., radical nephrectomy concomitant
with adjacent organ resection and/or total metastasect-
omy. On the other hand, 111 patients (61.3%) underwent
cytoreductive nephrectomy, while the remaining 52
(28.7%) did not undergo nephrectomy and received only
medical treatment. Further, 120 of the 129 patients
(93.0%) who underwent any kind of nephrectomy (cura-
tive or cytoreductive) also received postoperative im-
munotherapy, including IFN-α and/or IL-2. Among the
52 patients (92.3%) who did not undergo nephrectomy, 42
received immunotherapies. Molecular targeting agents, in-
cluding sorafenib, sunitinib, and/or everolimus, were
administered to 7 patients after 2008. Histopathologicanalysis proved that 134/181 (74.0%) patients had clear-
cell-RCC, and 174/181 (96.1%) had more than 1 organ
metastases (Table 1). At the end of the study period, in
April 2011, the follow-up period for all patients ranged
from 0.03 to 186 months (median: 28.6 months).
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All patients were staged according to the 2002 TNM
classification system [12]. We collected data on the
following clinicopathologic factors from the medical
records of the patients: patient age; sex; Eastern
Cooperative Oncology Group performance status (ECOG
PS); maximum tumor diameter; number of metastatic
organ sites; and levels of hemoglobin (Hb), lactate
dehydrogenase (LDH), alkaline phosphatase (ALP), cor-
rected calcium, and CRP when a patient was first seen.
The Hb level was categorized using a cutoff value of
the lower normal limit, and LDH and ALP levels, using a
cutoff value of 1.5× the normal limit; corrected calcium
was considered normal up to 10 mg/dL, as reported pre-
viously [1,12,13]. Maximum tumor diameter was divided
into two groups using median value.
Statistical analysis
The overall survival (OS) period was calculated from the
date of nephrectomy to death or last follow-up. For
patients who did not undergo nephrectomy, the survival
period was measured from the first diagnosis of RCC to
death or last follow-up. The differences between groups
were examined using the Mann–Whitney U or chi-
square test depending on the data set.
We determined the cutoff point of CRP according
to the sensitivity and specificity levels derived from the
receiver operating characteristic (ROC) curve plotted
using death before median survival period in the patient
cohort that underwent nephrectomy. Survival probabil-
ities were estimated using the Kaplan-Meier method,
and the resultant curves were statistically tested by the
log-rank method. Cox proportional hazards model was
used for univariate and multivariate analyses. Significance
was set at P< 0.10, which was used as the criterion for
determining variable entry and removal from the multi-
variate analysis. All data were analyzed using the SPSS
software package (SPSS, Chicago, Illinois). All statistical
tests were two-sided and were considered to be statisti-
cally significant for P< 0.05.
Results
Patient characteristics
We initially tried to figure out what kind of clinical fac-
tors might influence on the selection of initial nephrec-
tomy for AM-RCC patient although the study was
retrospective, non-randomized observational setting. We
therefore compared the clinicopathologic characteristics
of patients who underwent curative or cytoreductive
nephrectomy with those of patients who did not
undergo nephrectomy. As expected, older patient age
(P= 0.003), larger tumor size (P= 0.004), and poorer
ECOG PS (P < 0.001) were observed in the non-
nephrectomy group compared to the nephrectomygroup (Table 1). With respect to the metastatic organ
sites, only the liver showed a higher incidence in the
non-nephrectomy group than in the other group
(P= 0.008); no apparent intergroup differences were
noted in the incidence of metastasis at any other organ
sites (P= 0.295; Table 1).
Survival distribution
Next, we analyzed the overall survival period for patients
who underwent nephrectomy and those who did not.
As reported previously, nephrectomy provided strong
survival advantage for AM-RCC patients. The median
survival for the 129 patients who underwent nephrec-
tomy and the 52 patients who did not undergo nephrec-
tomy was 23.9 months and 2.80 months (P < 0.001),
respectively (Figure 1).
C-reactive protein and patient survival
From the medical records, we collected data regarding
CRP levels at the onset in 143/181 AM-RCC patients.
The patients exhibited varying serum CRP levels, ran-
ging from undetectable to 212 mg/L, and 103/143
(72.0%) patients had abnormal CRP values (over
3.00 mg/L; Figure 2).
We determined the CRP cutoff point by means of
ROC analysis for the cohort of patients who under-
went nephrectomy (n= 95). From the ROC analysis, we
found 2 reasonable CRP cutoff points, 18.0 and 67.0 mg/L
(Figure 3); accordingly, we classified the patients into nor-
mal/mildly elevated CRP (≤18.0 mg/L), elevated CRP
(18.0–67.0 mg/L), and highly elevated CRP (≥67.0 mg/L)
groups. Kaplan-Meier analyses revealed statistically signifi-
cant differences between these 3 groups, and the median
overall survival periods were 53.2, 12.6, and 4.20 months
in the normal/mildly elevated CRP, elevated CRP, and
highly elevated CRP groups, respectively (Figure 4).
We next applied the same CRP cutoff and grouping
system to the AM-RCC cohort of patients who did not
undergo nephrectomy. We found that the 3 CRP levels
defined were again correlated with patient survival and
that patients with normal/mildly elevated CRP levels
clearly showed longer survival periods (Figure 5). The
median overall survival periods were 24.4, 2.83, and
1.54 months in the normal/mildly elevated CRP, elevated
CRP, and highly elevated CRP groups, respectively.
Since patients with highly elevated (≥67.0 mg/L) levels
of CRP showed poor prognosis despite the treatment
procedures, i.e., nephrectomy or medical treatment only
(median OS: 4.20 and 1.54 months, respectively), we
compared these 2 groups. Kaplan-Meier analysis showed
that the 2 groups did not differ statistically (log-rank:
P= 0.703). Although the 2 groups differed slightly with
respect to patient characteristics and backgrounds, the
data suggested that initial nephrectomy did not seem to
No nephrectomy 
(n = 28)






















Figure 1 Kaplan-Meier overall survival probability curves for the 2 treatment groups (patients who underwent nephrectomy and those
who did not).
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highly elevated CRP levels.
CRP as an independent prognostic parameter for AM-RCC
Lastly, we tested the association of patient survival with
CRP values against that with other established clinical
and biochemical parameters, including the Memorial
Sloan-Kettering Cancer Center (MSKCC) risk factors
[1,2]. Survival analysis was performed for 81 patients
who underwent nephrectomy and for whom the
complete clinical and biochemical data were available.
Cox univariate analyses demonstrated that several clin-
icopathologic parameters, including age; ECOG PS;
number of metastatic organ sites; and levels of Hb, ALP,
and CRP, showed a statistically significant association
with OS (Table 2). On the other hand, neither LDH






Figure 2 Histogram of elevated CRP value in patients with AM-RCC. A
abnormal CRP values (>3.00 mg/L) at initial presentation; the graph wcorrelated with survival lengths. Further Cox multivari-
ate analysis demonstrated that ECOG PS, number of
metastatic organ sites, and the CRP levels defined in this
study remained statistically significant independent para-
meters for survival (Table 2).
Discussion
CRP is a standardized and widely used serum indicator
of acute-phase response in conditions such as acute
inflammations, infections, tissue or organ necrosis, and
malignancies [14]. Some types of RCCs can induce sys-
temic inflammations by expressing various cytokines
such as IL-1, tumor necrosis factor, and mostly IL-6
[15]. In vitro experimental studies showed some renal
tumors themselves are actually capable of producing IL-6
[15]. Furthermore, RCC, especially of the aggressive
phenotype, is often accompanied by tumor necrosis [16].200.0180.0160.0140.0120.0
ue
mg/ L
mong 143 patients with AM-RCC, 103 (72.0%) exhibited


















Figure 3 ROC curve of CRP values for overall rate of death before the median survival period. Cohort of patients with AM-RCC who
underwent nephrectomy (n= 95; median survival = 25.7 months) was analyzed.
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reflected by the serum CRP levels of patients with AM-
RCC. Additionally, in case of other malignancies, CRP
had been found to inhibit apoptosis of carcinoma cells,
thereby directly regulating tumor cell growth and survival
[17]. In fact, we often encounter cases of AM-RCC in
which the patient’s CRP level fluctuates in accordance
with disease control and/or progression. Several studies
have also indicated that elevated CRP is a poor prognostic
indicator for RCC [9-11,18,19]. However, almost all the
CRP cutoff points reported previously have been single
values. These cutoff points range from 1.0 to 10.0 mg/L
and vary widely from study to study, despite the fact that
in the majority of studies, the cutoff point was defined on


















Figure 4 Kaplan-Meier overall survival probability curves according to
nephrectomy (n = 95).study, we found that over 70% of the patients with AM-
RCC showed abnormal CRP values, with a relatively wide
dynamic range of up to 200 mg/L (Figure 2). In fact,
when we initially applied previously reported cutoff
points to our patient cohort, we were unable to define
any CRP-based grouping system that could afford a ra-
tional assessment of survival risk (data not shown). In this
study, we initially determined the 2 CRP cutoff points
18.0 and 67.0 mg/L in the nephrectomy patient cohort by
means of ROC analysis. We then found that the CRP 3
grouping was a more suitable model for the risk stratifica-
tion of AM-RCC patients because it was also applicable
for patients who did not undergo nephrectomy (Figure 5).
A number of prognostic parameters have been studied




































Figure 5 Kaplan-Meier overall survival probability curves according to the 3 CRP-defined groups of patients who did not undergo
nephrectomy (n = 27).
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RCC, the most well-established and validated ones are
Memorial Sloan-Kettering Cancer Center (MSKCC) risk
factors [1] and predictors of short survival proposed by
the NCCN practice guidelines [12]. In these models,
however, CRP has not been enlisted as a significant fac-
tor. In our Cox models, we found that the risk factors
associated with shorter survivals were high CRP level,
low ECOG PS, and high number of metastatic organ
sites (Table 2). On the other hand, Hb and ALP levels
were not found to be independent parameters. More-
over, sex, maximum tumor diameter, LDH and corrected
calcium levels did not appear to be statistically signifi-
cant factors even in the univariate analyses. Thus, our
results were considerably different from the recommen-
dations of the MSKCC and NCCN guidelines [1,12].
One of the major reasons for this discrepancy should be
the treatment modalities. In our regression model, all
patients underwent nephrectomy as the initial treatment.
On the other hand, the prognostic factors defined in the
MSKCC or NCCN guidelines were originally elucidated
from patients receiving non-surgical medical treatments.
Another possible reason might be the racial differences.
Enrolled patients in our study were Japanese Asian
populations. Naito S, et al. suggested that Japanese
patients with AM-RCC showed better prognosis than
non-Asian cohort [22]. Such racial differences might
affect the biological character of tumors, leading to dif-
ferences in present report. On the basis of our data, we
recommend that for patients with AM-RCC who are
being considered for nephrectomy as the initial treat-
ment option, more importance should be given to the
CRP levels, ECOG PS, and the number of metastatic
organ sites than other patient characteristics, such as
ALP, Hb, LDH, and serum Ca levels.Reports indicate that surgical complications occur in
20–22 % of patients with AM-RCC, and therefore, surgi-
cal approaches should not be adopted indiscriminately
[5,6]. Our data revealed that the patient group with
highly elevated CRP (≥67.0 mg/L) showed very poor
prognosis despite of treatment (median OS: 4.20 months
in the nephrectomy group and 1.54 months in the non-
nephrectomy group) (Figures 4 and 5). In this patient
subgroup, the indications of initial surgical intervention
should be assessed very carefully. On the other hand, the
normal/mildly elevated CRP (≤18.0 mg/L) group showed
relatively good prognosis even for patients who did
not undergo nephrectomy (median OS: 24.2 months;
Figure 5). Our data also suggested that the initial neph-
rectomy seemed to provide considerable survival advan-
tages to patients with normal/mildly elevated and
presumably elevated CRP levels (Figure 4). Thus, surgi-
cal approaches appear to be beneficial for these patient
groups although other parameters need to be evaluated
to validate this finding.
The majority of the patients analyzed in this study
belonged to the so-called cytokine era. Currently, a
number of treatment options, such as surgery, immuno-
therapy, and a series of molecular targeting agents, are
available for patients with AM-RCC. It has been well-
demonstrated that both MSKCC risk factors and NCCN
guideline parameters, which were originally established
in the cytokine era, are useful even in the molecular tar-
geting era. Therefore, we expect that the current CRP
grouping model will be important in the risk classifi-
cation of patients with AM-RCC, even in the current
molecular targeting era. Further prospective studies are
now required to validate our findings.
There are inherent limitations to this study. Because
of its retrospective design, the confounding factors and
Table 2 Univariate and multivariate Cox regression analysis of overall survival among patients AM-RCC who
underwent nephrectomy of any kind (n= 81)
Parameter Univariate Multivariate
n P HR 95% CI P HR 95% CI
Age, yr
<62.0 39 1.00 1.00
≥62.0 42 0.026 1.87 1.08−3.26 0.177 1.51 0.083−2.76
Sex
Female 25 1.00 X
Male 56 0.840 0.94 0.53-1.68
ECOG PS
0 44 1.00 1.00
1 32 0.001 2.54 1.45-4.34 0.012 2.22 1.19-4.16
≥2 5 0.000 7.89 2.56-24.3 0.022 4.18 1.23-14.3
Hb
≥Lower normal limit 45 1.00 1.00
<Lower normal limit 36 0.047 1.72 1.01-2.92 0.862 1.06 0.58-1.93
LDH
≦Normal limit × 1.5 51 1.00 x
>Normal limit × 1.5 30 0.567 1.17 0.69-2.00
ALP
≦Normal limit × 1.5 78 1.00 1.00
>Normal limit × 1.5 3 0.026 3.92 1.18-13.0 0.510 0.60 0.13-2.76
Corrected Ca, mg/dL
<10.0 50 1.00 x
≥10.0 31 0.404 0.79 0.45-138
Max. tumor diameter, cm
<8.0 41 1.00 x
≥8.0 40 0.381 0.78 0.45-1.35
No. of metastatic organ sites
0,1 35 1.00
≥2 46 0.054 1.72 0.99-2.99 0.011 2.33 1.21-4.48
CRP, mg/L
≦18.0 49 1.00 1.00
>18.0, <67. 20 0.057 1.86 0.98-3.54 0.036 2.06 1.05-4.05
0≥ 67.0 12 0.000 6.66 3.16-14.01 0.001 5.85 2.07-16.56
*X, excluded from the multivariate analysis.
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could in prospective, randomized studies. Especially, there
is clearly a selection bias in any comparison between
the nephrectomy and non-nephrectomy groups since
the latter were clearly more advanced/unresectable/non-
surgical candidates. However, despite of no clear criteria
whether surgery was performed or not, Table 1 revealed
significant differeneces; patient age, tumor size, ECOG PS
and liver metastasis. That suggested that these parameters
had impacts on our decision making. We believed that
might be also useful information for clinical practice
[3,4,6].Conclusions
Our study demonstrated that the serum CRP level is a sta-
tistically significant prognostic parameter for patients with
AM-RCC. Risk factors of OS were CRP (≤18.0 mg/L,
>18.0 and <67.0 mg/L, and ≥67.0 mg/L), ECOG PS (0, 1,
and ≥2), number of metastatic organ sites (0–1 and ≥2).
The study also revealed that patients with highly elevated
CRP levels (≥67.0 mg/L) had a considerably poor progno-
sis despite treatment. The data indicated that pretreat-
ment serum CRP level could be one of the most reliable
prognostic factors that can help decide whether to per-
form surgical procedures for patients with AM-RCC.
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